LISATA THERAPEUTICS INC (LSTA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:LSTA • US1280583022

4.54 USD
-0.06 (-1.3%)
At close: Feb 6, 2026
4.5858 USD
+0.05 (+1.01%)
After Hours: 2/6/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall LSTA gets a fundamental rating of 2 out of 10. We evaluated LSTA against 523 industry peers in the Biotechnology industry. LSTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LSTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • LSTA had negative earnings in the past year.
  • In the past year LSTA has reported a negative cash flow from operations.
  • In the past 5 years LSTA always reported negative net income.
  • In the past 5 years LSTA always reported negative operating cash flow.
LSTA Yearly Net Income VS EBIT VS OCF VS FCFLSTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • The Return On Assets of LSTA (-83.84%) is worse than 69.33% of its industry peers.
  • Looking at the Return On Equity, with a value of -105.00%, LSTA is in line with its industry, outperforming 44.76% of the companies in the same industry.
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROIC N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
LSTA Yearly ROA, ROE, ROICLSTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LSTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSTA Yearly Profit, Operating, Gross MarginsLSTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • LSTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LSTA has been increased compared to 1 year ago.
  • LSTA has more shares outstanding than it did 5 years ago.
  • LSTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LSTA Yearly Shares OutstandingLSTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
LSTA Yearly Total Debt VS Total AssetsLSTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -32.72, we must say that LSTA is in the distress zone and has some risk of bankruptcy.
  • LSTA has a Altman-Z score of -32.72. This is amonst the worse of the industry: LSTA underperforms 88.38% of its industry peers.
  • There is no outstanding debt for LSTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.72
ROIC/WACCN/A
WACC8.86%
LSTA Yearly LT Debt VS Equity VS FCFLSTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • LSTA has a Current Ratio of 4.72. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of LSTA (4.72) is comparable to the rest of the industry.
  • LSTA has a Quick Ratio of 4.72. This indicates that LSTA is financially healthy and has no problem in meeting its short term obligations.
  • LSTA's Quick ratio of 4.72 is in line compared to the rest of the industry. LSTA outperforms 56.19% of its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.72
LSTA Yearly Current Assets VS Current LiabilitesLSTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • LSTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.14%, which is quite good.
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 12.18% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.19%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSTA Yearly Revenue VS EstimatesLSTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2022 2024 2027 2028 2029 2030 2031 50M 100M 150M 200M
LSTA Yearly EPS VS EstimatesLSTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LSTA. In the last year negative earnings were reported.
  • Also next year LSTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSTA Price Earnings VS Forward Price EarningsLSTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSTA Per share dataLSTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LSTA's earnings are expected to grow with 19.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.17%
EPS Next 3Y19.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for LSTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LISATA THERAPEUTICS INC

NASDAQ:LSTA (2/6/2026, 8:00:00 PM)

After market: 4.5858 +0.05 (+1.01%)

4.54

-0.06 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners8.38%
Inst Owner Change-1.47%
Ins Owners7.17%
Ins Owner Change22.8%
Market Cap40.04M
Revenue(TTM)1.07M
Net Income(TTM)-18.24M
Analysts82.22
Price Target9.69 (113.44%)
Short Float %0.11%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.38%
Min EPS beat(2)10.21%
Max EPS beat(2)18.55%
EPS beat(4)3
Avg EPS beat(4)14.02%
Min EPS beat(4)-1.74%
Max EPS beat(4)29.05%
EPS beat(8)7
Avg EPS beat(8)17.46%
EPS beat(12)11
Avg EPS beat(12)19.51%
EPS beat(16)13
Avg EPS beat(16)-30.07%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.92%
PT rev (3m)-54.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.4%
EPS NY rev (1m)-8.64%
EPS NY rev (3m)-4.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 37.42
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0.12
BVpS1.97
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.84%
ROE -105%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.5%
ROA(5y)-44.09%
ROE(3y)-64.1%
ROE(5y)-49.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.72
Altman-Z -32.72
F-Score4
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.95%
EPS Next Y1.19%
EPS Next 2Y26.17%
EPS Next 3Y19.8%
EPS Next 5Y12.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.04%
EBIT Next 3Y-10.73%
EBIT Next 5Y-1.14%
FCF growth 1Y23.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.19%
OCF growth 3YN/A
OCF growth 5YN/A

LISATA THERAPEUTICS INC / LSTA FAQ

What is the ChartMill fundamental rating of LISATA THERAPEUTICS INC (LSTA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LSTA.


What is the valuation status for LSTA stock?

ChartMill assigns a valuation rating of 0 / 10 to LISATA THERAPEUTICS INC (LSTA). This can be considered as Overvalued.


How profitable is LISATA THERAPEUTICS INC (LSTA) stock?

LISATA THERAPEUTICS INC (LSTA) has a profitability rating of 0 / 10.


How financially healthy is LISATA THERAPEUTICS INC?

The financial health rating of LISATA THERAPEUTICS INC (LSTA) is 6 / 10.


What is the earnings growth outlook for LISATA THERAPEUTICS INC?

The Earnings per Share (EPS) of LISATA THERAPEUTICS INC (LSTA) is expected to grow by 1.19% in the next year.